Genetic variants in human carbonyl reductase 3 (CBR3) and their influence on doxorubicin pharmacokinetics in Asian breast cancer patients

被引：0
|
作者：
Fan, L.
Guo, J. Y.
Wong, C. I.
Lim, R.
Yap, H. L.
Khoo, Y. M.
Iau, P.
Goh, B. C.
Lee, H. S.
Lee, S. C.
机构：
[1] Natl Univ Singapore, Singapore, Singapore
[2] Natl Univ Singapore Hosp, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2505
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Investigation of the pharmacogenetic influences of carbonyl reductase on doxorubicin and doxorubicinol in breast cancer patients.
    Gaudy, Allison
    Fetterly, Gerald J.
    Adjei, Alex A.
    O'Connor, Tracey L.
    Quinones, Adolfo
    Blanco, Javier G.
    Ferguson, Daniel
    Meholick, Patricia D.
    Kalabus, James
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Influence of PXR haplotype variants on paclitaxel pharmacokinetics and pharmacodynamics in Asian cancer patients
    Chowbay, B.
    Sandanaraj, E.
    Lal, S.
    Wang, Z. P.
    Kulkarni, T.
    Lim, W. T.
    Peter, C. S. Ang
    Tan, E. H.
    EJC SUPPLEMENTS, 2008, 6 (12): : 63 - 63
  • [23] Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients
    A. L. Wong
    K. Y. Seng
    E. M. Ong
    L. Z. Wang
    H. Oscar
    M. T. Cordero
    R. Copones
    L. Fan
    S. H. Tan
    B. C. Goh
    S. C. Lee
    Breast Cancer Research and Treatment, 2014, 144 : 143 - 152
  • [24] Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients
    Wong, A. L.
    Seng, K. Y.
    Ong, E. M.
    Wang, L. Z.
    Oscar, H.
    Cordero, M. T.
    Copones, R.
    Fan, L.
    Tan, S. H.
    Goh, B. C.
    Lee, S. C.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 144 (01) : 143 - 152
  • [25] Influence of PXR Haplotype Variants on Paclitaxel and Docetaxel Pharmacokinetics and Pharmacodynamics in Asian Cancer Patients
    Chowbay, Balram
    Sandanaraj, Edwin
    Lal, Suman
    Wang Zhenping
    Teck, Lim Wan
    Siang, Ang Cher
    Lee, Edmund
    Huat, Tan Eng
    DRUG METABOLISM REVIEWS, 2009, 41 : 56 - 56
  • [26] Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients
    Voon, Pei Jye
    Yap, Hui Ling
    Ma, Cho-Yee-Thu
    Lu, Fan
    Wong, Andrea L. A.
    Sapari, Nur Sabrina
    Soong, Richie
    Soh, Thomas I. P.
    Goh, Boon-Cher
    Lee, How-Sung
    Lee, Soo-Chin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (06) : 1497 - 1505
  • [27] COMPARATIVE PHARMACOKINETICS OF DOXORUBICIN GIVEN BY 3 DIFFERENT SCHEDULES WITH EQUAL DOSE INTENSITY IN PATIENTS WITH BREAST-CANCER
    TWELVES, CJ
    DOBBS, NA
    ALDHOUS, M
    HARPER, PG
    RUBENS, RD
    RICHARDS, MA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (04) : 302 - 307
  • [28] Pharmacokinetics of intravenous etoposide in patients with breast cancer:: influence of dose escalation and cyclophosphamide and doxorubicin coadministration
    Busse, D
    Würthwein, G
    Hinske, C
    Hempel, G
    Fromm, MF
    Eichelbaum, M
    Kroemer, HK
    Busch, FW
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 366 (03) : 218 - 225
  • [29] Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration
    Dagmar Busse
    Gudrun Würthwein
    Christiane Hinske
    Georg Hempel
    Martin F. Fromm
    Michel Eichelbaum
    Heyo K. Kroemer
    Friedrich W. Busch
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 366 : 218 - 225
  • [30] The influence of doxorubicin on PTEN and PI3K-Akt-mTOR signaling in human breast cancer
    Austreid, E.
    Knappskog, S.
    Lonning, P. E.
    Eikesdal, H. P.
    CANCER RESEARCH, 2013, 73
12345